Eli Lilly and Co.

Eli Lilly announces $7-billion merger, with eye on wakefulness drugs. The deal with London and Boston-based biotech company Centessa could have implications for treating Alzheimer’s.

The lawsuit alleges insulin can cost Eli Lilly just a few dollars to produce, while some consumers are charged hundreds of dollars.

Indiana University and Eli Lilly are working together to expand clinical trials in the state. IU President Pamela Whitten and Lilly CEO David Ricks signed a $40 million, five-year deal Wednesday.

The Lilly announcement will extend an agreement aimed at accelerating medicine development and bolstering the workforce-talent pipeline.

The new research and development site will combine research, process development and clinical trial manufacturing capabilities into one plant.

The LillyDirect website connects people with independent telehealth providers, tailored support and other disease management resources. The website also allows patients to have some medications delivered directly to their home.

Federal regulators say a new version of the popular diabetes treatment Mounjaro can be sold as a weight-loss drug. The Food and Drug Administration approved Zepbound on Wednesday. The drug has been shown to help dieters lose about a quarter of their body weight, or 60 pounds. It is the latest diabetes drug approved for weight loss, joining Novo Nordisk’s Wegovy, a high-dose version of Ozempic. Short supply and high costs have limited access to both medications. The FDA approved the new drug for people considered obese or for those who are overweight and have a weight-related health condition.

The ‘Lilly Scholars @ Ivy Tech' program will build on Ivy Tech’s existing biopharmaceutical manufacturing certification program. Eli Lilly will fund the $15 million project for the next five years.

Eli Lilly will cut prices for some older insulins later this year and immediately expand a cap on costs insured patients pay to fill prescriptions.

The Indianapolis-based pharmaceutical company, Eli Lilly and Company, announced Wednesday it will lower the prices of its branded insulin by 70 percent and will introduce more price caps for its non-branded insulin.